CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Radius and Karo Bio announced today that the companies have entered into a licensing agreement in which Radius acquires the exclusive worldwide rights, excluding the Nordic countries, to a new class of selective androgen receptor modulators (SARMs) discovered by Karo Bio. Radius is advancing these SARM compounds in preclinical studies for the treatment of osteoporosis and frailty associated with muscle loss.
